Skip to main content

Table 1 Patient demographic characteristics

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

  Placebo (N = 27) Namilumab
20 mg (N = 28) 80 mg (N = 25) 150 mg (N = 28)
Age, years 47.2 ± 13.45 46.1 ± 10.07 49.0 ± 9.60 51.3 ± 14.13
Female 23 (85.2) 22 (78.6) 17 (68.0) 22 (78.6)
Race
 Asian 6 (22.2) 4 (14.3) 3 (12.0) 5 (17.9)
 White 21 (77.8) 24 (85.7) 22 (88.0) 22 (78.6)
 Multiracial 0 0 0 1 (3.6)
BMI, kg/m2 23.75 ± 5.542 24.91 ± 5.210 27.16 ± 5.605 25.92 ± 6.313
BMI categories
 < 30 kg/m2 24 (88.9) 23 (82.1) 16 (64.0) 22 (78.6)
 ≥ 30 kg/m2 3 (11.1) 5 (17.9) 9 (36.0) 6 (21.4)
Smoking classification
 Nonsmoker 16 (59.3) 19 (67.9) 18 (72.0) 18 (64.3)
 Ex-smoker 6 (22.2) 5 (17.9) 5 (20.0) 6 (21.4)
 Current smoker 5 (18.5) 4 (14.3) 2 (8.0) 4 (14.3)
Region
 Ex-Japan 23 (85.2) 24 (85.7) 22 (88.0) 23 (82.1)
 Japan 4 (14.8) 4 (14.3) 3 (12.0) 5 (17.9)
  1. Values are mean ± SD or n (%). BMI body mass index
\